Skip to main content
SpringerLink
Log in

Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer

  • REVIEW
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Cardiovascular disease (CVD) is the leading cause of non-cancer mortality in men with prostate cancer. This review summarizes the existing and emerging literature examining the cardiometabolic effects of androgen deprivation therapy (ADT) in prostate cancer.

Recent Findings

The evidence behind the metabolic effects of ADT is derived from older studies and has not been validated in modern cohorts. Most of the newer studies focus on the risk of cardiovascular disease (CVD) with ADT. Recently published studies like the HERO and PRONOUNCE trials have once again sparked debate about the effects of different types and durations of ADT on cardiovascular outcomes.

Summary

The link between ADT and CVD is inherently complex with a majority of the evidence collected from population-based or non-randomized trials without enriching for high-risk populations. Ongoing clinical trials may provide more informative data to guide the cardiovascular care of prostate cancer survivors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

    Article  PubMed  Google Scholar 

  2. Resnick MJ, Lacchetti C, Bergman J, Hauke RJ, Hoffman KE, Kungel TM, et al. Prostate cancer survivorship care guideline: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2015;33(9):1078–85.

    Article  PubMed  Google Scholar 

  3. Kim J, Freeman K, Ayala A, Mullen M, Sun Z, Rhee JW. Cardiovascular impact of androgen deprivation therapy: from basic biology to clinical practice. Curr Oncol Rep. 2023;25(9):965–77.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tisseverasinghe S, Tolba M, Saad F, Gravis G, Bahoric B, Niazi T. Should prostate cancer patients with history of cardiovascular events be preferentially treated with luteinizing hormone-releasing hormone antagonists? J Clin Oncol. 2022;40(36):4173–7.

    Article  PubMed  Google Scholar 

  5. Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS, et al. Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016. JAMA Netw Open. 2021;4(8):e2119568.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ye Y, Zheng Y, Miao Q, Ruan H, Zhang X. Causes of death among prostate cancer patients aged 40 years and older in the United States. Front Oncol. 2022;1(12):914875.

    Article  Google Scholar 

  7. Gupta D, Lee Chuy K, Yang JC, Bates M, Lombardo M, Steingart RM. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract. 2018;14(10):580–7.

    Article  PubMed  Google Scholar 

  8. Smith MR, Finkelstein JS, Mcgovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603.

    Article  CAS  PubMed  Google Scholar 

  9. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer. Cancer. 2008;112(10):2188–94.

    Article  CAS  PubMed  Google Scholar 

  10. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271–6.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91(4):1305–8.

    Article  CAS  PubMed  Google Scholar 

  12. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer: evidence for a distinct hypogonadal metabolic syndrome? Urology. 2008;71(2):318–22.

    Article  PubMed  Google Scholar 

  13. Alibhai SMH, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27(21):3452–8.

    Article  PubMed  Google Scholar 

  14. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.

    Article  CAS  PubMed  Google Scholar 

  15. Keating NL, Liu PH, O’Malley AJ, Freedland SJ, Smith MR. Androgen deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol. 2014;65(4):816–24.

    Article  CAS  PubMed  Google Scholar 

  16. Bourghardt J, Wilhelmson ASK, Alexanderson C, De Gendt K, Verhoeven G, Krettek A, et al. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology. 2010;151(11):5428–37.

    Article  CAS  PubMed  Google Scholar 

  17. Nathan L, Shi W, Dinh H, Mukherjee TK, Wang X, Lusis AJ, et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A. 2001;98(6):3589–93.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  18. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261–7.

    Article  CAS  PubMed  Google Scholar 

  19. Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Rajkumar C. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J Androl. 2009;30(4):410–5.

    Article  CAS  PubMed  Google Scholar 

  20. Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, et al. Improving research for prostate cancer survivorship: a statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urol Oncol Semin Orig Investig. 2020;38(3):83–93.

    Google Scholar 

  21. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020 Jun 4;382(23):2187–96. ** Pivotal HERO trial identifying decreased MACE with relugolix compared to GnRH agonists.

  22. Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol. 2020;203(6):1109–16.

    Article  PubMed  Google Scholar 

  23. Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;6(21):241.

    Article  Google Scholar 

  24. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021 Oct 19;144(16):1295–307. ** Only phase III trial with CVD as the primary outcome associated with GnRH agonists and antagonists.

  25. Bonsu JM, Guha A, Charles L, Yildiz VO, Wei L, Baker B, et al. Reporting of cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies. J Am Coll Cardiol. 2020 Feb 18;75(6):620–8. *Analysis identifying incorrect reporting of cardiovascular events in cancer clinical trials

  26. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448–56.

    Article  PubMed  Google Scholar 

  27. Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65(4):704–9.

    Article  CAS  PubMed  Google Scholar 

  28. O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243–51.

    Article  PubMed  Google Scholar 

  29. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS ONE. 2014;9(9):e107516.

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  30. Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto AS, et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol. 2015;33(9):1281–9.

    Article  CAS  PubMed  Google Scholar 

  31. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–96.

    Article  PubMed  Google Scholar 

  32. Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y, et al. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer. 2016;16(1):180.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kim DK, Lee HS, Park JY, Kim JW, Ha JS, Kim JH, et al. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study. J Cancer Res Clin Oncol. 2021;147(4):1217–26.

    Article  CAS  PubMed  Google Scholar 

  34. Nguyen PL, Je Y, Schutz FAB, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359–66.

    Article  CAS  PubMed  Google Scholar 

  35. Hopmans SN, Duivenvoorden WCM, Werstuck GH, Klotz L, Pinthus JH. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol Semin Orig Investig. 2014;32(8):1126–34.

    CAS  Google Scholar 

  36. Knutsson A, Hsiung S, Celik S, Rattik S, Mattisson IY, Wigren M, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE−/− mice. Sci Rep. 2016;18(6):26220.

    Article  ADS  Google Scholar 

  37. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65(3):565–73.

    Article  CAS  PubMed  Google Scholar 

  38. Gu L, Li X, Liu W. Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: a systematic review and meta-analysis. Front Endocrinol. 2023;31(14):1157857.

    Article  Google Scholar 

  39. Davey P, Kirby MG. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World J Urol. 2021;39(2):307–15.

    Article  CAS  PubMed  Google Scholar 

  40. Perrone V, DegliEsposti L, Giacomini E, Veronesi C, Blini V, Oderda M. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. Ther Clin Risk Manag. 2020;7(16):393–401.

    Article  Google Scholar 

  41. George G, Garmo H, Scailteux LM, Balusson F, Coster GD, Schutter HD, et al. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: real-world evidence from five databases. Int J Cancer. 2021;148(9):2203.

    Article  CAS  PubMed  Google Scholar 

  42. Scailteux LM, Vincendeau S, Balusson F, Leclercq C, Happe A, Le Nautout B, et al. Androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010–2013 French Health Insurance data. Eur J Cancer Oxf Engl. 2017;1990(77):99–108.

    Article  Google Scholar 

  43. Crawford ED, Hafron JM, Debruyne F, Wallis C, Chang S, Garnick MB. Cardiovascular risk in prostate cancer patients using luteinizing hormone-releasing hormone agonists or a gonadotropin-releasing hormone antagonist. J Urol. 2023;211(1):63–70. https://doi.org/10.1097/JU.0000000000003721.

    Article  PubMed  Google Scholar 

  44. Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol. 2019;202(6):1199–208.

    Article  PubMed  Google Scholar 

  45. Jin C, Fan Y, Meng Y, Shen C, Wang Y, Hu S, et al. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients. Prostate Cancer Prostatic Dis. 2016;19(4):333–9.

    Article  CAS  PubMed  Google Scholar 

  46. Morgans AK, Ebrahimi R, Bobbili PJ, Nwokeji E, Gandhi R, Desai R, et al. Association of intermittent or continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with nonmetastatic prostate cancer. J Clin Oncol. 2023;41:83–83.

    Article  Google Scholar 

  47. Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2(4):453–61.

    Article  PubMed  PubMed Central  Google Scholar 

  48. McMaster University. The role of androgen deprivation therapy in cardiovascular disease - a longitudinal prostate cancer study (RADICAL PC1) & a RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2) [Internet]. clinicaltrials.gov; 2023 Sep [cited 2022 Dec 31]. Report No.: NCT03127631. https://clinicaltrials.gov/study/NCT03127631

  49. Narayan V. The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC): initial pilot feasibility study to assess patient awareness and risk mitigation [Internet]. clinicaltrials.gov; 2023 Oct [cited 2022 Dec 31]. Report No.: NCT06064149. https://clinicaltrials.gov/study/NCT06064149

  50. M.D. Anderson Cancer Center. Modifying metabolic syndrome and cardiovascular risk for prostate cancer patients on ADT using a supervised exercise program and continuous Fitbit monitoring [Internet]. clinicaltrials.gov; 2023 Mar [cited 2022 Dec 31]. Report No.: NCT05054296. https://clinicaltrials.gov/study/NCT05054296

  51. Myovant Sciences GmbH. Relugolix versus leuprolide in patients with prostate cancer: a randomized, open-label study to assess major adverse cardiovascular events (REPLACE-CV) [Internet]. clinicaltrials.gov; 2023 Nov [cited 2022 Dec 31]. Report No.: NCT05605964. https://clinicaltrials.gov/study/NCT05605964

Download references

Author information

Authors and Affiliations

  1. Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA, 02215, USA

    Daniel Sentana-Lledo

  2. Dana-Farber Cancer Institute, Boston, MA, USA

    Alicia K. Morgans

Authors
  1. Daniel Sentana-Lledo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alicia K. Morgans
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

D.S. and A.K.M. wrote manuscript and reviewed together; D.S. prepared tables.

Corresponding author

Correspondence to Daniel Sentana-Lledo.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflict of Interest

The authors declare that they have no competing interests relevant to this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sentana-Lledo, D., Morgans, A.K. Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer. Curr Oncol Rep 26, 299–306 (2024). https://doi.org/10.1007/s11912-024-01512-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-024-01512-x

Keywords

Search

Navigation